Us regulators withdrew permission for emergency use of antimalarial hydroxychloroquine for the treatment of patients with coronavirus infection. The reason for the revocation was a lack of data about the effectiveness of the drug for this indication, reports the BBC.
An emergency permit was issued by the FDA in March 2020. However, data from recent clinical studies indicate the lack of effectiveness of the antimalarial in the treatment of coronavirus infection.
Previously, the use of hydroxychloroquine refused the EU. European regulators made this decision due to security concerns: in an article published in The Lancet, said that in patients receiving hydroxychloroquine, it was observed an increased risk of death and heart rhythm disturbances.